Aptamer Group Secures $2.2m Series A Investment
Aptamer Group Ltd secures Series A Investment from Netherlands-based investment firm Meneldor.
Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.
Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market in the coming years. Our world-leading discovery platform will allow us to continue capitalising on the inherent benefits of aptamers over other technologies in the custom research tools, diagnostics and therapeutic markets. This investment will allow us to rapidly drive the business forward; focusing on our preclinical discovery pipeline, including the development of Aptamer Drug Conjugates (ApDCs) – which are set to become a revolutionary approach to targeted drug delivery.
The funding round was supported by Netherlands-based biopharmaceutical investment company, Meneldor – founded by Dutch entrepreneurs Frans van Dalen and Paul Lelieveld. Frans is a founding partner of Synthon Holdings and has 30 years’ experience in the development of New Biological Entities (NBEs) and Biosimilars. Paul is a serial investor and has invested in numerous early-stage life-science companies including Ablynx, which recently sold to Sanofi for $4.8bn.
Says Meneldor: “We believe that aptamer technology represents a paradigm shift in drug delivery methodology. We have invested in Aptamer Group Ltd due to their progressive approach and unique technology platform, which can select aptamers significantly better and faster with the superior binding properties. We believe that this will lead to the development of new medicines and represents an exciting investment opportunity. We believe this company and its management team has the potential of becoming the next Ablynx.”
We are now actively seeking additional development partners in the CRO, Diagnostics and Therapeutics development space.